Phathom Pharmaceuticals (PHAT) Total Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Total Liabilities data on file, last reported at $642.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $642.1 million, up 1.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $642.1 million (up 1.5% YoY), and the FY2025 annual result was $697.3 million, up 10.35% from the prior year.
• Total Liabilities declined to $642.1 million in Q1 2026 per PHAT's latest filing, from $697.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $697.3 million in Q4 2025 and troughed at $111.0 million in Q1 2022.
• A 5-year average of $445.7 million and a median of $505.0 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities surged 167.43% in 2022, then advanced 1.5% in 2026.
• A 5-year view of Total Liabilities shows it stood at $239.6 million in 2022, then jumped by 103.07% to $486.6 million in 2023, then increased by 29.86% to $631.9 million in 2024, then increased by 10.35% to $697.3 million in 2025, then retreated by 7.92% to $642.1 million in 2026.
• Business Quant data shows PHAT's Total Liabilities at $642.1 million in Q1 2026, $697.3 million in Q4 2025, and $662.8 million in Q3 2025.